Sight-saving Therapeutics for the Treatment of Neovascular Age-related Macular Degeneration

1.00 CME
1.00 ABO MOC
$0 FEE
namd cme


Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.

Support Statement

This activity is supported by an educational grant from Allergan, Inc.

Activity Description

Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence due to treatment burden remains a significant problem. Continuing advances in the refinement of dosing frequency protocols, as well as the development of therapies and devices that promise to extend dosing intervals, have the potential to overcome treatment burden, further enhancing long-term visual outcomes. Within this 4-part podcast series, experts in the field discuss current therapy dosing schedules and their impact on visual outcomes and patient adherence, assess novel mechanisms of action of emerging therapies that have the potential to improve visual acuity, as well as evaluate new and emerging therapeutic and dosing options that have the potential to reduce treatment burden in patients with nAMD.

Target Audience

The intended audience for this activity is retina specialists and other health care professionals involved in the management of patients with neovascular age-related macular degeneration.

Learning Objective(s)

Upon successful completion of this activity, participants should be better able to:

  • Summarize how dosing schedules for current agents used to treat neovascular age-related macular degeneration (nAMD) may affect visual outcomes as well as patient adherence and satisfaction.
  • Explore novel mechanisms of action of emerging therapies that may improve visual acuity and outcomes in patients with nAMD.
  • Evaluate new and emerging therapeutics that are efficacious, require less frequent administration, and may improve patient adherence and satisfaction with treatment for nAMD.

Activity Chair

Arshad M. Khanani, MD, MA
Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada
Reno, NV


Nancy M. Holekamp, MD
Director, Retina Services
Pepose Vision Institute
Professor of Clinical Ophthalmology
Washington University School of Medicine
St. Louis, MO

Peter K. Kaiser, MD
Chaney Family Endowed Chair in Ophthalmology Research
Professor of Ophthalmology
Cole Eye Institute
Cleveland Clinic Lerner College of Medicine
Cleveland, OH 


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Successful completion of this CME activity, which is defined as answering ALL the posttest questions and includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning requirements for the American Board of Ophthalmology’s Maintenance of Certification (ABO MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting MOC credit. Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn MOC credits equivalent to the amount of CME credits claimed for the activity. The CME activity provider will submit learner completion information to the ACCME for the purpose of granting ABO MOC credits within 30 days of activity completion.

This enduring material is approved for 1 year from the date of original release, July 31, 2020, through July 30, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, listen to the podcast, and complete the posttest and evaluation. Provide only one (1) correct answer for each of the questions. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.

Activity Chair and Faculty report the following relationship(s)

Nancy M. Holekamp, MD
Intellectual Property/Patent: Katalyst Surgical
Consulting Fee: Acucela, Allergan, Clearside, Gemini, Genentech, Gyroscope, Katalyst Surgical, Lineage Cell Therapeutics, Notal Vision, Novartis, Regeneron
Speakers Bureau: Allergan, Genentech, Novartis, Regeneron, Spark Therapeutics
Contracted Research: Gemini, Genentech, Gyroscope
Ownership Interest: Katalyst Surgical

Peter K. Kaiser, MD
Consulting Fee: Aerie, Aerpio, Alcon, Allegro, Allergan, Bausch + Lomb, Bayer, Biogen Idec, Boehringer Ingelheim, Chengdu Kanghong, Clearside, Eyevensys, Formycon/BioEq GmbH, Galecto Biotech, Galimedix, Hospira, Irenix, jCyte, Kala, Kodiak, NGM Biopharmaceuticals, Novartis, Ocugenix, Omeros, Opthea, Oxurion (ThromboGenics), Regeneron, Regenxbio, Retinal Sciences, Roivant, Santen, SciFluor, Shire, Spark Therapeutics, Stealth Biotherapeutics, Verena (Digisight), Zeiss

Arshad M. Khanani, MD, MA
Consulting Fee: Adverum, Alcon, Allegro, Allergan, Bausch + Lomb, EyePoint, Gemini Therapeutics, Genentech, Graybug Vision, Gyroscope, Kodiak, Novartis, Opthea, Oxurion, PolyPhotonix, Recens Medical, Regenxbio
Speakers Bureau: Allergan, Novartis
Contracted Research: Adverum, Allegro, Allergan, Gemini Therapeutics, Genentech, Graybug Vision, Gyroscope, Iveric Bio, Kodiak, Novartis, Opthea, Oxurion, Recens Medical, Regenxbio

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at